부산대학교 도서관

Key Clinical Message For potentially resectable HCC, a more aggressive conversion therapy strategy (high‐intensity combined with multiple treatment modalities) can be used. Abstract Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide. The best treatment for HCC is radical surgical resection, but 70%–80% of patients are ineligible for surgery. Although conversion therapy is an established treatment strategy for various solid tumors, there is no uniform protocol for treating HCC. In this case, we present a 69‐year‐old male patient diagnosed with massive HCC with Barcelona clinical liver cancer (BCLC) stage B. Because of the insufficient volume of the future liver remnant, we believed radical surgical resection was temporarily impossible. Therefore, the patient received conversion therapy, including four cycles of transcatheter arterial embolization (TAE) and hepatic arterial infusion chemotherapy (HAIC‐Folfox), lenvatinib (8 mg orally once a day), and tislelizumab (an anti‐PD‐1 antibody, 200 mg intravenously once every 3 weeks). Fortunately, the patient achieved a good treatment response (smaller lesions and improved liver function) and underwent radical surgery finally. There was no clinical evidence of recurrence at 6 months of follow‐up. For potentially resectable HCC, this case reveals that a more aggressive conversion therapy strategy (high‐intensity combined with multiple treatment modalities) can be used.